Newsletter · · Ashutosh Agarwal

Insurers Pick Margin Over Members as CMS Freezes ACA Agents - Managed Care Under Pressure - Week of September 26, 2026

The Managed Care Under Pressure weekly podcast intelligence brief for the week of September 26, 2026. CMS froze new ACA marketplace agents through the 2027 open enrollment season while Medicare Advantage carriers cut broker commissions and exited counties, putting margin over membership across Centene, UnitedHealth, Humana and CVS.

Managed Care Under Pressure

Week of September 26, 2026: Insurers Pick Margin Over Members as CMS Freezes ACA Agents

TL;DR

  • CMS turned last week's rumor into a rule. On September 22, the agency published an interim final rule that stops any insurance agent who wasn't already registered for 2026 from signing people up on the federal ACA marketplace until February 1, 2027. That covers the whole 2027 open enrollment season, which starts November 1. CMS's own estimate is that about 19,000 new agents are locked out, roughly 7,000 of whom would actually have sold policies. It also gave itself standing authority to do this again. For the exchange insurers, led by Centene (CNC), that means a smaller and more heavily policed sign-up season on top of the subsidy cliff.
  • Medicare Advantage insurers are picking profit over growth, and the podcasts caught the tactics in plain view. One consumer podcast documented how UnitedHealthcare and other carriers cut broker commissions in markets where a competitor collapsed. A broker quoted one carrier rep: "We don't want everybody that sunk UCARE on our plan... this is how we're going to curb enrollments." A broker-run podcast described a "record number" of plan pullbacks heading into the Medicare enrollment season that opens October 15. Separately, a new Health Affairs study found plans absorbed the three-year V28 risk-adjustment cut without raising premiums, trimming extra benefits like hearing, meals and gym memberships instead.
  • Honest read on the week: plenty of podcasts, very little investor voice. We found over 30 candidate episodes but no human sell-side or buy-side analyst making a stock call. We also found nothing new on UNH's September 30 New York-Presbyterian contract deadline, UNH's Justice Department coding probe, Star Ratings litigation, or anything specific to Humana. What did fill in: harder numbers on Medicaid work requirements (CMS projects 2.7 million fewer enrollees in 2027) and a GLP-1 story that has moved from the doctor's office to the benefits office, with employers now dropping coverage of the entire drug class.

What's new

1. The ACA agent freeze is now official, and it's bigger than a one-time move.

On The Seven Figures Or Bust Podcast!, hosted by independent insurance agents (role: distribution/agents, not investors), the hosts recorded an "emergency" episode the morning CMS published the rule. It runs 56 pages and is formally titled "Patient Protection and Affordable Care Act; Temporary Moratoria on Certain Agent and Broker Registration to Participate in the Exchanges" (CMS-9872-IFC). The hosts walked through what it actually does:

  • Who is locked out: "Agents and brokers who do not already have a plan year 2026 exchange agreement cannot complete registration for plan year 2027 until the moratorium lifts. And it will lift February 1st, 2027." Because ACA open enrollment begins November 1, "a brand new agent who wasn't already registered for plan year 2026 is locked out of FFE marketplace registration during the upcoming open enrollment period." (The FFE, or federally facilitated exchange, is the HealthCare.gov marketplace used by states like Texas, Florida and Utah. States that run fully independent exchanges are outside the rule.)
  • The size: CMS estimates "roughly 19,000 people would otherwise have registered, with approximately a bit under 7,000 expected to have actually written business." It expects about 80% of existing agents to return.
  • The part most people will miss: the rule adds a new regulation giving HHS standing power to impose temporary freezes whenever it decides agent activity "creates an unacceptable risk to marketplace integrity." In the hosts' words, "this isn't necessarily a one-time tool... they can flip this like a switch at any point in time."

The Seven Figures Or Bust Podcast!: "CMS Passed The Moratorium.... (Emergency Podcast)" (2026-09-22)

The day before, the same show interviewed Ronnell Nolan, founder of the trade group Health Agents for America (HAFA) (role: industry association executive and lobbyist). She said she had been on a call with "CMS brass" before the rule leaked and told them it was a "bad idea." Her read is openly political: "It's politics. It's midterm elections. They're trying to show everybody we're doing something about the fraud." She also raised a risk the Medicare side should watch. The rule as leaked did not say whether it covered ACA only, and "we also have heard... that it could be Medicare Advantage." The final rule is ACA-only. Still, the hosts added "never say never. This is the same governing body." Nolan said HAFA had calls with Senator Schumer's and Senator Cassidy's offices seeking bipartisan pushback. The Seven Figures Or Bust Podcast!: "Episode 273 - Talking CMS Moratorium For Agents With Ronnell Nolan Of HAFA!" (2026-09-21)

Why it matters: Brokers drive a large share of ACA sign-ups, especially among the low-income enrollees who were the focus of last week's fraud data (Dr. Oz's roughly 3 million Florida enrollees against about 636,000 actually eligible). Cutting off new agents before open enrollment, on top of the expired enhanced subsidies, points to a smaller 2027 exchange pool. It could be a cleaner pool if fraud is squeezed out, or a sicker one if healthy, price-sensitive people simply don't sign up. For CNC, the largest exchange insurer in our coverage, that is the key uncertainty for 2027 exchange margins. The standing-authority clause matters too: CMS now has a tool it can reach for every year, and possibly one day in Medicare.

2. Medicare Advantage insurers are shrinking on purpose, and brokers are describing exactly how.

An Arm and a Leg, a public-radio-style consumer health-cost podcast from reporter Dan Weissman with Emily Pisecretta (role: journalists), spent an episode reconstructing what happened in Minnesota last fall. It is a real-world preview of the 2027 enrollment season that opens October 15.

  • UCare, a 40-year-old nonprofit plan with some of the most generous Medicare Advantage offerings in the state, collapsed. Its members, at least 160,000 in the first wave, had to find new coverage.
  • At the same time, "UnitedHealthcare, Blue Cross, Aetna, Humana, all of them canceled Medicare Advantage plans in counties all over the state. Three counties were left with no Medicare Advantage plans at all."
  • Nationally, "almost 3 million seniors across the country had plans in 2025 that were going to stop being offered to them in 2026," and "major insurers have already announced intentions to dump plans that currently cover more than 2 million seniors" for the coming year.

The most striking detail came from Minnesota broker Allison Ebert. Just before open enrollment, her UnitedHealthcare contact called: "I just want to let you know before you get the email, we're not paying commissions this year." Then "one by one, thereafter, all the major carriers, except for Allina Health Aetna, followed suit." When she asked why, she says a carrier rep told her: "With UCARE exiting the market... We don't want everybody that sunk UCARE on our plan. And so this is how we're going to curb enrollments." Carriers have told brokers that "about 80% of the sales comes through brokers like us," so cutting commissions is a very effective brake on sign-ups. For seniors, the result was fewer choices and more cost. The $0-premium plans in affected areas "were gone," along with popular extras like SilverSneakers gym memberships. The state Medicare hotline had two-hour wait times. An Arm and a Leg: "Medicare is more broken than we thought" (2026-09-24)

The broker podcasts confirm the same thing is happening again right now. On The Seven Figures Or Bust Podcast!, the hosts described a "record number" of service area reductions (SARs, meaning an insurer stops offering a plan in a county) and a market "heavily impacted by noncommissionable plans." One agency owner called the coming season "a freaking bloodbath in a good way" for agents, because so many seniors must switch. Another told of a regional carrier that is "pretty much like not open for new business... and they're sending their leads off to independent agents to write other carriers. I never thought I would ever live to see that in my lifetime." The Seven Figures Or Bust Podcast!: "Episode 275 - How To Capture TONS Of New Business From Terminating MA Plans!" (2026-09-25)

There's a knock-on effect for Medicare Supplement (Medigap) insurers. Seniors whose plan is cancelled get "guaranteed issue" rights: they can buy certain Medigap plans with no health questions. The hosts said carriers are telling agents to use guaranteed issue when a client qualifies, as CMS rules require, but pay almost nothing for it: sometimes a "95% reduction of your normal commission," a "one-time commission of 20 bucks," or nothing at all. The reason is that this is the riskiest business a carrier can write. The hosts put Medigap loss ratios (the share of premium paid out in claims) at "around 86 percent... the highest it's been in decades." The Seven Figures Or Bust Podcast!: "Episode 274 - Carriers Are Telling Agents To Do GI Med Supps For No Commissions!" (2026-09-24)

Why it matters: This is the "margin over membership" playbook in action, and it cuts both ways. For investors, cancelling unprofitable counties and throttling sign-ups where a failed competitor's sick members are looking for a new home is exactly how UNH, HUM, CVS/Aetna and ELV repair Medicare Advantage margins for 2027. The bear side is just as clear. A reporter-led podcast now has a broker on tape quoting a carrier about avoiding sick members, which is the kind of story that draws political attention ahead of the midterms. And the members the MA plans push out don't vanish. Many land in guaranteed-issue Medigap, which is already running its worst loss ratios in decades. Keep in mind that UNH, through its AARP-branded business, is the largest Medigap writer, so it sits on both sides of this shift.

3. New research: plans absorbed the V28 payment cut by quietly trimming extras, not raising prices.

On A Health Podyssey, the podcast of the journal Health Affairs (role: health-policy researchers), the host interviewed the lead author of a new study in the journal's September issue. It measures what the V28 risk-adjustment model actually did to Medicare Advantage plans. (Risk adjustment pays plans more for sicker members based on the diagnoses they record. V28 is the updated model that "lowered the ability of MA plans to have discretion in what level of severity gets coded.") Key points:

  • CMS originally projected V28 would cut risk scores by "about two percentage points and result in $7 billion savings" to the Medicare trust fund in 2024 alone. It was phased in one-third at a time over 2024–2026, so 2026 is the first fully loaded year.
  • Plans "didn't [pass it through] for the most part... premiums and cost sharing were largely unaffected."
  • Instead, plans cut supplemental benefits at the margin, with "reductions in hearing coverage, I think meal coverage, gym memberships and some other categories." Each individual cut was small, but "when you aggregate all these reductions... they might end up aggregating to something that's more noticeable."
  • The study controlled for county benchmark changes and Star Ratings bonus changes. The author flagged what the study couldn't see: narrower networks, more aggressive prior authorization, and claim denials. The author's policy takeaway: "supplemental benefits are likely to be hit the hardest when payments are cut to MA."

A Health Podyssey: "Medicare Advantage Risk Adjustment: Why CMS's Payment Cuts Didn't Raise Premiums" (2026-09-22)

Why it matters: This is the first solid look at how plans actually responded to V28, and it supports both sides of the debate. Bulls can say the industry took a multi-billion-dollar coding cut without having to raise premiums, which suggests plans can stay competitive and still have room to adjust. Bears can say the money had to come from somewhere, and if not premiums, then margins (which is what 2024–2025 earnings showed), extras, and the network and prior-authorization levers the study couldn't measure. With V28 now fully phased in, 2027 bids are the first in years without an extra risk-model cut on top. That's a quiet positive for the Medicare Advantage-heavy names, HUM above all.

4. GLP-1s: employers are dropping the whole drug class, and states are backing away too.

On Bloomberg's Everybody's Business, hosts Max Chafkin and Stacey Vanek-Smith interviewed Bloomberg workplace reporter Taylor Nicole Rogers (role: journalists) about a Businessweek story on employers cutting GLP-1 weight-loss drugs such as Wegovy and Zepbound entirely. Her key points:

  • It is historically unusual. Benefits economists told her "there's never been an entire category of drugs that employers have carved out before. Usually, if there's one drug that's too expensive, they'll give you an alternative."
  • The cost math: "an employer could be paying between $500 and $700 per month just for one employee's treatment," at a time when "about 1 in 10 Americans are on GLP-1." Employer health coverage already costs about $18,000–$19,000 per employee, and employers face a 6.7% average cost increase.
  • The savings case is unproven. Some employers, such as Bank of America, are willing to spend "tens of millions" hoping to prevent later costs. But a study last year found employers were spending more because patients returned for follow-up visits, "and that kind of erased the savings."
  • Human impact: one worker went from a $25 copay to about $300 a month for an unapproved compounded version after her employer dropped coverage. Union surveys found members weighing groceries against the drug.

Everybody's Business: "Why Are Employers Dropping GLP-1 Coverage?" (2026-09-25)

The public side is tightening as well. On The Dr. Francavilla Show, obesity-medicine physicians Dr. Francavilla (host) and Dr. Doug Maready (role: clinicians and coverage advocates) said "four states have rescinded coverage because of budget overruns. California was one of the big ones... their budget just went berserk." They cited a negotiated Medicare/Medicaid price of "$245 exactly." Their Arizona Medicaid analysis put obesity coverage at "$7 and $20 million a year," which new federal price concessions would largely offset (about $8 million in savings on diabetes GLP-1s). Even so, "the big, beautiful bill has already cut billions of dollars in their budget. So they don't have any room." They were more upbeat on the Medicare GLP-1 bridge program that began July 1: "it's the easiest prior auth we do in our practice... we get an approval instantly if they meet the criteria." The Dr. Francavilla Show: "GLP and Obesity Treatment Coverage with Dr. Doug Maready" (2026-09-21)

One more data point came from Crain's Daily Gist. Illinois's 2023 decision to cover GLP-1s for weight loss in its state employee plan "cost the state $147 million in fiscal year 2025," and Governor Pritzker, who disclosed his own GLP-1 use, "acknowledged state budget pressures could force future coverage adjustments." Crain's Daily Gist: "Chicago's dueling renters ordinances, explained" (2026-09-21)

Why it matters: This is the first week in a while the GLP-1 podcasts turned to who pays rather than clinical results. Employers and states pulling back reduces the cost burden on commercial and Medicaid books, but most large-employer coverage is self-funded. That means the savings go mainly to the employer, while insurers and PBMs (Caremark, Express Scripts, Optum Rx) lose some script volume and administrative fees. The pressure point for Medicare Advantage is the opposite. If Medicare's bridge program makes approvals "instant," utilization among seniors is heading up, and that flows into Part D and MA drug trend. We could not confirm from the podcasts how the bridge program's cost is split, so treat that as a question to put to management on Q3 calls.

5. Medicaid work requirements now have hard enrollment numbers and a timeline for the hit.

On HFMA's Voices in Healthcare Finance, from the Healthcare Financial Management Association, Nick Hutt spoke with policy analyst Katie Gilfillan (role: policy experts). Starting January 1, 2027, in 43 Medicaid expansion states, most expansion adults must show 80 hours a month of work, job search, volunteering or education. The figures: the Congressional Budget Office projects Medicaid coverage "will drop by 5.2 million people as of 2034" from the work requirement, and "just looking at 2027, CMS has projected a decrease of 2.7 million enrollees." Expansion adults also move to redeterminations every six months. CMS just issued three-tier guidance on the "medically frail" exemption, under which providers may need to supply documentation when the state can't verify a condition. The timing point for investors: "You're not going to see this immediate single financial event... this impact is going to build over the course of the calendar year 2027." HFMA's Voices in Healthcare Finance: "Compliance audit efficiency, a new learning experience from HFMA and updates on Medicaid eligibility" (2026-09-22)

The fraud angle came up on Tradeoffs (role: health-policy journalists, with the New York Medicaid director, the head of Massachusetts's Medicaid Fraud Control Unit, and a former Nebraska Medicaid director). The episode reset some commonly misused numbers. State fraud units recovered about $2 billion in 2025, roughly 0.2% of Medicaid spending, and almost all of that was provider fraud, not beneficiaries. The $37 billion "improper payments" figure (6% of federal Medicaid spending) "is not actually a fraud number"; three-quarters of it is documentation problems. The most significant new item: CMS has withheld $2.5 billion from California and Minnesota over fraud concerns, "the largest deferrals ever," tied to fast growth in in-home care spending. Tradeoffs: "States Weigh In on Medicaid Fraud" (2026-09-24)

And on Achieving Health (Forvis Mazars), John Beaman, CEO of Adventist Health (role: operator, health-system CEO), described safety-net hospitals as standing on a "three-legged stool" of state-directed payments, 340B, and ACA coverage expansion, with work requirements now set to "chew into that leg." His hospitals are partnering with the managed Medicaid plans in each county on enrollment education. The host explained the plans' motive in one line: "stable enrollment is more reflective of how their PMPM is priced. Obviously, they lose enrollment, they lose a piece of that PMPM." (PMPM means per-member-per-month, the fixed monthly fee states pay Medicaid plans for each enrollee.) Achieving Health: "How Rural and Safety Net Hospitals Can Thrive: John Beaman, Adventist Health" (2026-09-23)

Why it matters: Last week a Cain Brothers banker argued Medicaid rates are finally catching up to the sicker post-pandemic population. This week put a number on the next wave: roughly 2.7 million fewer enrollees in 2027 alone, phased in through the year as six-month redeterminations roll through. People who fail paperwork-heavy requirements tend to be healthier, lower users, so this likely worsens acuity again just as rates catch up. For CNC, MOH and ELV, the 2027 question is whether states set mid-year rate adjustments fast enough to match a pool that shrinks and gets sicker month by month.

Also worth a note (operator/provider side): On Working Healthcare, billing and coding consultant Stephanie Allard (role: provider-side consultant) said CVS is suing Tennessee over a law that would bar insurers from owning PBMs and pharmacies, claiming CVS said "they would have to close all the CVSs in Tennessee" if it stands. We could not independently verify the Tennessee details from the podcast; the pattern matches CVS's 2025 challenge to a similar Arkansas law. She also named Cigna, Aetna and Humana as frequent sources of downcoding and bundled-code denials, and cited a striking statistic: "only 11 and a half percent of denied Medicare Advantage prior authorizations were actually appealed in 2024. But when they are appealed, over 80 percent get overturned." Working Healthcare: "Ep. 121 - Medicare Advantage: The Payer Tactics Practices Need to Know (ft. Stephanie Allard)" (2026-09-22)

The debate

Bull: the industry is doing exactly what it needs to do, and 2027 is the payoff year. The evidence this week is that insurers are being disciplined. Medicare Advantage carriers are leaving unprofitable counties, cutting commissions to avoid a failed rival's high-cost members, and quietly trimming extras rather than raising premiums (An Arm and a Leg; Seven Figures Or Bust; A Health Podyssey). V28 is now fully phased in, so 2027 bids no longer face an extra risk-model cut. On the ACA side, a CMS crackdown on fraud-prone new agents could leave a cleaner, more honestly enrolled pool. In Medicaid, last week's rate-lookback argument still holds: rates are starting to reflect today's sicker members. Employers dropping GLP-1s takes one of the fastest-growing cost lines off part of the commercial book. Put it together and 2027 looks like a repricing year where margins recover.

Bear: every lever insurers pull creates a new problem, and Washington is watching. Margin repair through county exits and commission cuts is now documented on a consumer podcast, with a broker quoting a carrier about avoiding sick members, less than two months before the midterms. The V28 study shows the payment cut came out of benefits and margins, and the author flagged denials and narrow networks as the likely next levers, exactly the practices attracting the most political heat (the 11.5% appeal rate and 80% overturn rate will be quoted). Medicaid faces a new 2.7 million-member shrink in 2027 that probably removes the healthiest members first, which could undo the rate catch-up before it arrives. The ACA pool shrinks again with fewer agents and no enhanced subsidies. And CMS just showed it will use blunt, fast, rule-by-interim-final tools (agent moratoria, record $2.5 billion Medicaid deferrals) on this sector. That is regulatory risk no multiple fully prices.

Our read: This week's material leans toward the bull case on 2027 margins but the bear case on political risk. The companies are doing the right things for profits, but those same actions are what draw political scrutiny.

Stocks in play

No podcast this week gave a human analyst's stock call or valuation view on any of these names. The notes below combine this week's podcast evidence with the standing setup.

UNH (UnitedHealth)

  • Bull: Named on a podcast as one of the carriers cutting MA commissions and exiting counties, which is margin discipline. As the largest Medigap writer (AARP-branded), it can capture some of the seniors pushed out of MA.
  • Bear: The "we're not paying commissions this year" quote is attributed to a UnitedHealthcare contact, which makes it the face of the "curbing enrollment" story. Guaranteed-issue Medigap inflows are the worst-risk business in a line already at about 86% loss ratios. The DOJ MA-coding overhang is unchanged (no news).
  • Next catalyst: September 30 New York-Presbyterian network deadline (no update on the podcasts this week); Q3 FY2026 earnings October 13 (before open), where 2027 MA footprint and membership guidance are the key items.

HUM (Humana)

  • Bull: The most Medicare Advantage-heavy name, so the biggest beneficiary of V28 being fully phased in and of industry-wide pricing discipline.
  • Bear: Named alongside UNH, Aetna and Blue Cross as cancelling MA plans in Minnesota counties, and named for downcoding by a provider consultant. The political risk of the MA "curb enrollment" story falls hardest on the pure-play.
  • Next catalyst: 2027 Star Ratings (typically released in October); AEP opens October 15; Q3 FY2026 earnings November 6. (No Humana-specific news this week.)

CVS (CVS Health / Aetna / Caremark)

  • Bull: Aetna (via the Allina Health Aetna joint venture) was the one major carrier that reportedly kept paying Minnesota broker commissions, which suggests selective growth appetite. Caremark scale.
  • Bear: A reported new legal fight over a Tennessee law that would bar insurers from owning pharmacies (unverified beyond the podcast), on top of last week's 340B hospital lawsuits. Aetna is named for downcoding. Employer GLP-1 carve-outs trim PBM volume.
  • Next catalyst: Status of the Tennessee and 340B litigation; Q3 FY2026 earnings October 28.

CI (Cigna / Evernorth / Express Scripts)

  • Bull: The least exposed to government programs, so it largely avoids the MA exit and Medicaid work-requirement stories.
  • Bear: Express Scripts is exposed to employer GLP-1 carve-outs (fewer scripts and rebates) and to state PBM-ownership laws like the one described in Tennessee. Named for downcoding.
  • Next catalyst: Employer 2027 benefit decisions on GLP-1s; Q3 FY2026 earnings October 29.

ELV (Elevance)

  • Bull: Diversified across MA, Medicaid and commercial; Medicaid rate catch-up helps.
  • Bear: Exposed to all three pressure points at once: a smaller 2027 Medicaid pool (2.7 million CMS estimate), a smaller ACA pool (agent freeze plus subsidy loss), and the same industry-wide MA footprint pullback.
  • Next catalyst: Q3 FY2026 earnings October 20, with commentary on 2027 Medicaid rates and exchange pricing.

CNC (Centene)

  • Bull: If the agent freeze squeezes out fraudulent enrollment, the remaining exchange book could be cleaner and priced more accurately.
  • Bear: The most exposed name to both this week's ACA agent freeze and next year's Medicaid work requirements. Enrollment shrinks in both businesses in 2027, and the people who leave are likely to be the healthier ones.
  • Next catalyst: ACA open enrollment starts November 1 with no new agents allowed; Q3 FY2026 earnings October 27.

MOH (Molina)

  • Bull: A Medicaid pure-play, so the most levered to any 2027 rate catch-up.
  • Bear: Also the most levered to the 2.7 million Medicaid enrollment drop, and to CMS's willingness to withhold federal money from states (the $2.5 billion deferrals to California and Minnesota).
  • Next catalyst: Q3 FY2026 earnings October 22; state 2027 rate updates.

Read-throughs

  • Medicaid and exchange insurers (CNC, MOH): This week brought two confirmed shrinks for 2027: the ACA pool (agent freeze through February 1, 2027 plus no enhanced subsidies) and the Medicaid pool (2.7 million fewer enrollees in 2027 per CMS, built up gradually over the year). Both likely shed healthier members first. The offsets are the rate lookback catching up (last week's Cain Brothers point) and, in the ACA, possibly less fraud. Watch Q3 calls for 2027 exchange pricing and any state mid-year rate language.
  • PBMs and Optum-style services arms: Employers dropping the whole GLP-1 class means lower script volume for Caremark, Express Scripts and Optum Rx, though they keep administrative fees on everything else. The structural threat is state PBM-ownership laws. A provider consultant says CVS is now fighting one in Tennessee, and a SOA reinsurance podcast noted gene therapies at "about three and a half million bucks" per case, with "probably... 30 of them out there," which keeps specialty drug trend a live risk for every PBM-owning insurer. SOA Podcasts: "Health Community: The View from the Tail" (2026-09-23)
  • Hospitals and providers on the other side: The Adventist Health CEO says all three supports under safety-net hospitals (state-directed payments, 340B, coverage expansion) are weakening at once. More uninsured and self-pay patients in 2027 mean more bad debt for hospitals, but also weaker hospitals with less leverage in contract talks with insurers. That is relevant to UNH's New York-Presbyterian standoff and to every 2027 network negotiation.
  • GLP-1 cost exposure: Commercial: employers and at least four states are pulling back, which eases cost pressure on fully insured books. Medicare: the bridge program is making approvals "instant," so utilization among seniors is likely rising. MA-heavy names (HUM, UNH) should be asked on Q3 calls how much of that cost they bear.

What changed vs last week

  • ACA: from "considering" to done. Last week CMS was weighing an agent moratorium. This week it was published (September 22) with dates (through February 1, 2027), a size (about 19,000 blocked, about 7,000 active sellers), and permanent standing authority. Advanced.
  • Medicare Advantage: new, concrete evidence on exits and enrollment-throttling. Last week's MA angle was the counted MTM Star measure. This week brought real-world evidence of the margin-over-membership strategy (commission cuts, county exits, "more than 2 million" seniors facing plan terminations) plus the first academic read on V28's effects. New.
  • Medicaid: from mechanism to magnitude. Last week explained why margins broke (acuity mismatch) and gave coverage-loss dates. This week put a CMS number on 2027 (2.7 million fewer enrollees), described the ramp (gradual through CY2027), and added record federal deferrals ($2.5 billion from California and Minnesota). Advanced.
  • GLP-1: finally payer-facing. Last week we flagged that GLP-1 podcasts were clinical and consumer only. This week they moved to coverage decisions: employers dropping the class, four states rescinding coverage, Illinois at $147 million. Gap partly closed, though still no insurer-level decision from a carrier.
  • Investor voice: gone again. Last week an AI-generated market show gave a CVS/UNH valuation frame. This week we found no market or investor podcast on the group at all. Regressed.
  • Not advanced / still absent: UNH–New York-Presbyterian (deadline is Wednesday, September 30, and no podcast covered it), UNH DOJ/RADV, Star Ratings litigation, Humana-specific news, Optum/CVS strategic-review chatter, Q3 pre-announcements, and follow-up on last week's CVS–Cigna "Cigna Health Works" launch or UNH's WellMed stake sale to TPG.

Next catalysts: September 30 NYP/UnitedHealthcare deadline · October 1 Medicaid immigrant-eligibility change · 2027 Star Ratings (October) · UNH Q3 on October 13 · AEP opens October 15 · ELV October 20 · MOH October 22 · CNC October 27 · CVS October 28 · CI October 29 · ACA open enrollment November 1 (under the agent freeze) · HUM November 6 · Medicaid work requirements January 1, 2027.